ANGLE PLC (LON:AGL) has potentially made a breakthrough in the detection, monitoring and treatment of prostate cancer based on the results of a study by the Barts Cancer Institute (BCI).
The data, presented in a poster at an international cancer symposium, show that ANGLE’s Parsotix liquid biopsy not only detects the killer disease, the device also allows doctors assess how aggressive the cancer is.
It means that using a simple Parsortix blood test, rather than an invasive and uncomfortable procedure, doctors can test for prostate cancer and decide whether just to monitor the patient in the early stages or intervene if the cancer is more aggressive.
Barts researcher, Dr Yong-Jie Lu, said: “The exciting part of this research is the potential for the Parsortix system to be used to assess the severity of the disease as well as to detect it.
“This meets a key medical need to avoid over-treatment as well as to ensure treatment is available for patients who need it."
The AIM listed medical devices firm said it will now work with BCI and other leading cancer centres to develop and implement clinical studies to validate the use of the Parsortix system “in the routine detection, assessment and treatment of prostate cancer patients”.
This process is likely to take 18 months.
ANGLE founder and chief executive Andrew Newland said: "These are highly encouraging results for the use of the Parsortix system for a clinical application in prostate cancer.
“This opens the potential of another highly differentiated liquid biopsy application for Parsortix in a key area of medical need, which cannot be addressed by ctDNA or antibody-based CTC systems, where there is the potential to improve patient care and at the same time reduce healthcare costs."
Partsortix, which has provided similarly encouraging results when used to detect breast and lung cancers, works by isolating circulating tumour cells (CTC) found in the bloodstream.
These CTCs provide the tell-tale signs of cancer.